Inhibition of vascular endothelial growth factor, a key contributor to the choroidal neovascularization associated with wet age-related macular degeneration, is the mode of action of several approved therapies, including aflibercept, which requires frequent intravitreal injections to provide clinical benefit. Lack of compliance with the dosing schedule may result in recurrence of active wet macular degeneration, leading to irreversible vision impairment. Gene therapy providing sustained anti-vascular endothelial growth factor levels in the retina following a single injection could drastically reduce the treatment burden and improve visual outcomes. ADVM-022, an adeno-associated virus vector encoding aflibercept, is optimized for intravitreal delivery and strong protein expression. Here, we report the long-term expression and efficacy of ADVM-022-derived aflibercept in a laser-induced choroidal neovascularization model in non-human primates. Intravitreal administration of ADVM-022 was well tolerated and resulted in sustained aflibercept levels. In addition, ADVM-022 administration 13 months before lasering prevented the occurrence of clinically relevant choroidal neovascularization lesions, similar to animals that received a bolus of intravitreal aflibercept (standard of care) at the time of lesioning. These results demonstrate that a single intravitreal administration of ADVM-022 may provide a safe and effective long-term treatment option for wet macular degeneration and may ultimately improve patients’ visual outcomes.
cAMP response element binding protein (CREB) is a key transcriptional regulator that
regulates the transcription of genes related with neuronal differentiation, synaptic plasticity, learning
and memory. Brain derived neurotrophic factor (BDNF), is a CREB dependent gene which
plays a pivotal role in the pathogenesis of epilepsy and central comorbid conditions associated with
epilepsy. However, the beneficial or detrimental consequences of CREB-BDNF activation on the
induction and/or progression of seizures depend specifically on the region of brain involved and the
time of activation. The bioactive molecules that alter the activity of CREB in a way to have specialized
effects in different brain regions and neural circuits involved could potentially be utilized for
therapeutic purposes. Flavonoids are the polyphenolic compounds which lead to phosphorylation of
CREB in the hippocampus, followed by increase in extracellular signal regulated kinase (ERK) and
BDNF. Several members of flavonoid family have also showed suppression of epileptic seizures via
interaction with CREB/BDNF pathway. Moreover, epilepsy is often accompanied by a number of
behavioural and psychological comorbid conditions that further gets aggravated by the use of conventional
antiepileptic drug therapy. Multiple studies have also supported the beneficial effects of
flavonoids in cognitive and memory impairments by upregulation of CREB-BDNF pathway. The
current review is an attempt to collate the available preclinical and clinical studies to establish the
therapeutic potential of various dietary flavonoids in comprehensive management of epilepsy with
relation to CREB-BDNF pathway.
Crocin is a pharmacologically active carotenoid pigment mainly present in the stigmas of Crocus sativus L. (Iridaceae). It has been well explored in experimental animal models of cognitive impairments, depression, anxiety and epilepsy. This study was designed to understand the effect of crocin on pentylenetetrazol (PTZ)-induced kindling development and its associated cognitive deficit in mouse. Crocin treatment at 5, 10 and 20 mg/kg p.o. doses showed a marked reduction in severity of PTZ-induced seizures. There was an increase in novel object preference index and discrimination ratio in the crocin-treated groups in the novel object recognition test. Its treatment also increased percentage spontaneous alternations in T-maze test at all the tested doses. Histopathological examination by Nissl staining showed a reduction in dark neurons in the hippocampal pyramidal layer of crocin-treated animals in contrast to vehicle control, indicating a decrease in neuronal damage. Biochemical estimations showed a significant increase in superoxide dismutase activity and reduced reactive oxygen species (ROS) in the hippocampus of crocin-treated animals. Immunohistochemistry results revealed attenuation in the levels of nuclear factor-κB (NF-κB) and phosphorylated NF-κB in the hippocampal sections of crocin-treated animals. The results of this study concluded that crocin treatment increased seizure threshold, thus inhibiting PTZ-induced kindling development and improving cognitive functions. The effect was found to be due to suppression of seizure-induced ROS generation and its linked NF-κB pathway-associated neuronal damage.
The results of the present study showed that apigenin treatment prevents cognitive deficit and reverses behaviour impairments, without altering seizures severity in kindled mice. The observed effects can be attributed to CREB-BDNF upregulation in the hippocampus.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.